李祥攀
肿瘤
放疗科科主任，放射物理基地副主任，主任医师，硕士/博士生导师
放疗科科主任，放射物理基地副主任，主任医师，硕士/博士生导师
导师介绍
| 姓名 | 李祥攀 |
| 出生年月 | 1976年6月 |
| 单位 | 武汉大学人民医院肿瘤中心 |
| 所属学科 | 临床医学-肿瘤学 |
| 职务、职称及头衔 | 放疗科科主任，放射物理基地副主任，主任医师，硕士/博士生导师 |
| lxp008cn@sina.com或rm001227@whu.edu.cn | |
| 联系方式 | 027-88041911转88085或18672360619 |
| 研究方向 |
1.肿瘤放射治疗 2.糖代谢及DNA损伤修复 |
| 个人简介 | 毕业于北京协和医学院，主要从事头颈部肿瘤、胶质瘤、肺癌等肿瘤诊疗工作；参与国家自然基金2两项，国家重大仪器专项子课题1项，获省科技厅、省卫生厅课题3项, CSCO基金一项；参编靶区勾画教材《肿瘤精准放疗靶区勾画图谱》、《肿瘤精准放射治疗临床要点》；在《Cell》、《Radiotherapy and Oncology》、《DNA Repair》、《中华放射肿瘤学杂志》等杂志上发表论文30余篇；连续三届获得武汉大学人民医院“医疗菁英”奖。 |
| 学术任职与荣誉 |
中国老年医学会肿瘤康复会肿瘤影像与康复治疗专家委员会副主委 中国老年学和老年医学学会肿瘤康复分会第二届委员会副主任委员 CRTOG脑转移工作委员会秘书长 中国抗癌协会神经肿瘤专业委员会常务委员 中国人体健康科技促进会头颈部肿瘤专委会常务委员 中国毒理学会特种医学专业委员会常务委员 湖北省临床肿瘤学会脑转移瘤专家委员会主任委员 中国抗癌协会放射肿瘤专业委员会青年委员 中西医结合肿瘤专业委员会颅底肿瘤委员会委员 湖北省科学技术厅科技专家库专家 湖北省放射卫生专家库人才专家 湖北省临床肿瘤学会常委 湖北省抗癌协会鼻咽癌专业委员会常委 湖北省肿瘤诊疗临床评价专家委员会常委 武汉医学会第四届放射肿瘤治疗学分会委员 湖北省抗癌协会小儿肿瘤第二届专委会委员 中国抗癌协会肿瘤放射治疗专委会第三届青年委员委员 中国医药教育协会肿瘤转移专委会常委 中国医疗保健国际交流促进会鼻咽癌防治分会委员副主任委员 武汉市医疗事故鉴定委员会专家 国家医疗器械技术审评中心外聘专家 期刊《中国图象图形学报》特邀审稿专家 期刊《湖北医药学院学报》编委 期刊《肝胆外科杂志》编委 |
| 教育履历 |
1997.06-2002.07湖北医药学院医学院临床医学专业本科生获学士学位 2004.09-2007.07广西医科大学医学院肿瘤学硕士研究生获硕士学位 2009.09-2012.07北京协和医学院肿瘤学博士研究生获博士学位 |
| 工作履历 |
2002.09-2004.07湖北医药学院附属太和医院住院医师 2007.09-2009.07湖北医药学院附属太和医院肿瘤科主治医师 2012.09-至今武汉大学人民医院放疗科副主任医师 |
| 成果获奖 |
1. 2018年荣获武汉大学人民医院首届中国医师节“医疗菁英”奖 2. 2019年荣获武汉大学人民医院第二届中国医师节“医疗菁英”奖 3.2021年荣获武汉大学人民医院第二届中国医师节“医疗菁英”奖 |
| 代表性论著 |
1.Zhao
C, Xiong K, Ji Z, Liu F, Li X P*. The Prognostic Value and Immunological Role
of STEAP1 in Pan-Cancer: A Result of Data-Based Analysis. Oxid Med Cell
Longev. 2022 Mar 11;2022:8297011. 2.Zhao P, Zou J, Zhou F, Zhu Y, Song Q, Yu D, Li X P*. Immune features of COVID-19 convalescent individuals revealed by a single-cell RNA sequencing. Int Immunopharmacol. 2022 Jul;108:108767. doi: 10.1016/j.intimp.2022.108767. Epub 2022 Apr 18. PMID: 35453072; PMCID: PMC9013654. 3.Jiang Y, Li X P*, Yang Y, Luo J, Ren X, Yuan J, Tong Q. LncRNA HOXC-AS1 Sponges miR-99a-3p and Upregulates MMP8, Ultimately Promoting Gastric Cancer. Cancers (Basel). 2022 Jul 20;14(14):3534. doi: 10.3390/cancers14143534. PMID: 35884594; PMCID: PMC9321533. 4.Li X P, Chu Y, Song Q, Hu Q. The Incidence-Based Mortality and Survival Trends in Patients with Gastric Signet Ring Cell Carcinoma. J Oncol. 2022 May 28;2022:3308801. 5.Zhao C, Xiong K, Adam A, Ji Z, Li X P*. Necroptosis Identifies Novel Molecular Phenotypes and Influences Tumor Immune Microenvironment of Lung Adenocarcinoma. Front Immunol. 2022 Jul 14;13:934494. doi: 10.3389/fimmu.2022.934494. PMID: 35911707; PMCID: PMC9331758. 6.Wu L, Liu J, Liang L, Mao M, Li X P*, Li T, Lang J, Wang Q. "Sandwich Therapy"-Immunotherapy Plus Concurrent Chemoradiotherapy for Advanced Esophagogastric Junction Carcinoma: Report of Two Cases and Literature Review. Front Oncol. 2022 May 25;12:794153. 7.Li X P, Chen Q, Ao J, Lin W, Qiu L, Cao R. Synthesis of novel 4,7-disubstituted quinoline derivatives as autophagy inducing agents via targeting stabilization of ATG5. Bioorg Chem. 2022 Jul 3;127:105998. doi: 10.1016/j.bioorg.2022.105998. Epub ahead of print. PMID: 35797861. 8.Li X P, Xiong K, Bi D, Zhao C. A Novel CRISPR/Cas9 Screening Potential Index for Prognostic and Immunological Prediction in Low-Grade Glioma. Front Genet. 2022 Apr 25;13:839884. 9.Zhao C, Xiong K, Zhao F, Adam A, Li X P*. Glycosylation-Related Genes Predict the Prognosis and Immune Fraction of Ovarian Cancer Patients Based on Weighted Gene Coexpression Network Analysis (WGCNA) and Machine Learning. Oxid Med Cell Longev. 2022 Mar 4;2022:3665617. 10.Li N, Xu T, Zhou Z, Li P, Jia G, Li X P*. Immunotherapy Combined With Chemotherapy for Postoperative Recurrent Penile Squamous Cell Carcinoma: A Case Report and Literature Review. Front Oncol. 2022 Mar 23;12:837547. 11.Ren X, Wen W, Fan X, Hou W, Su B, Cai P, Li J, Liu Y, Tang F, Zhang F, Yang Y, He J, Ma W, He J, Wang P, Cao Q, Chen F, Chen Y, Zhong X, Zhang S, Zhu L, Zhu P, Zou B, Zou J, Zuo Z, Bai F, Huang X, Zhou P, Jiang Q, Huang Z, Bei JX, Wei L, Bian XW, Liu X, Cheng T, Li X P*(共同通讯), Zhao P, Wang FS, Wang H, Su B, Zhang Z, Qu K, Wang X, Chen J, Jin R, Zhang Z. COVID-19 immune features revealed by a large-scale single-cell transcriptome atlas. Cell.2021.053(01):1-19. 12.He H, Xu T, Li P, Jia G, Li X P*, Song Q. Anti-PD-1 Immunotherapy Combined With Stereotactic Body Radiation Therapy and GM-CSF as Salvage Therapy in a PD-L1-Positive Patient With Refractory Metastatic Thyroid Hürthle Cell Carcinoma: A Case Report and Literature Review. Front Oncol. 2021 Nov 23;11:782646. 13.Yu D, Hu W, Chen L, Fu Z, Song Q, Li X P*. Effect of radiotherapy interruption due to COVID-19 outbreak - ScienceDirect[J]. Radiotherapy and Oncology, 2021, 155:1-2. 14.Haihua He, Tangpeng Xu, Ping Li, Guohua Jia, Xiangpan Li*, Qibin Song, Anti-PD-1 Immunotherapy Combined With Stereotactic Body Radiation Therapy and GM-CSF as Salvage Therapy in a PD-L1-Positive Patient With Refractory Metastatic Thyroid Hürthle Cell Carcinoma: A Case Report and Literature Review[J]. Frontiers in Oncology, 2021, 23(11):1-6. 15.Ping Li, Lulu Chen, Zheming Liu, Jinghui Pan, Dingyi Zhou, Hui Wang, Hongyun Gong, Zhenmin Fu, Qibin Song, Qian Min, Shasha Ruan, Tangpeng Xu, Fan Cheng*, Xiangpan Li*.Clinical features and short-term outcomes of elderly patients with COVID-19.[J]. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2020, 97 : 245-250. 16.Li, Xiangpan, Zhang, Huibo,Jia, Xuemei,Xu, Liming,Liu, Huali,Chen, Liang,Song, Qibin*,Hui, Zhouguang*.Survival benefit of radiotherapy in metastatic esophageal cancer: a population-based study[J]. Translational Cancer Research, 2019, 8(4) : 1074-1085. 17.Xue, Renyu,Peng, Yihan,Han, Baolin,Li, Xiangpan*,Chen, Yali,Pei, Huadong*. Metastasis suppressor NME1 promotes non-homologous end joining of DNA double-strand breaks.[J]. DNA repair, 2019, 77 : 27-35. 18.Li, Xiangpan, Zhang, Huibo, Wu, Xiaofei*. Long noncoding RNA DLX6-AS1 accelerates the glioma carcinogenesis by competing endogenous sponging miR-197-5p to relieve E2F1[J]. Gene, 2018, 686. 19.Li X P , Wu X . MiR-21-5p promotes the progression of non-small-cell lung cancer by regulating the expression of SMAD7[J]. Oncotargets & Therapy, 2018, Volume 11:8445-8454. 20.李祥攀,张惠博,俞建雄，俞建雄,宋启斌,肖建平..放射治疗对转移性鼻咽癌生存的影响——基于SEER数据库的回顾性研究[J].中华放射肿瘤学杂志, 2019, 28(1):5-12. |
| Name | XIANGPAN Li |
| Date of birth | Jun，1976 |
| Department | Oncology Department，Renmin Hospital,Wuhan University. |
| Title |
Radiation
Director, Deputy Director of the
Radiological Physics Base， Chief Physician, Master/Doctoral Supervisor |
| lxp008cn@sina.com or rm001227@whu.edu.cn | |
| TEL | 027-88041911-88085 or 18672360619 |
| Research Direction |
1.
Radiation oncology 2. Glucose metabolism and DNA damage repair |
| Personal Profile | He graduated from Peking Union Medical College, mainly engaged in the diagnosis and treatment of head and neck cancer, glioma, lung cancer and other cancers, and has been participated in 2 items for the National Natural Science Foundation, 1 item for the National Major Instrument Special Subproject,3 items from the provincial science and Technology Department, the Provincial Education Commission and the Provincial Health Department，and awarded 1 items from CSCO. He has also involved in compiling the target volume delineation teaching material Target Area Mapping Atlas of Precision Radiation Therapy for Tumors and Tumor Precise Radiotherapy Clinical Key Points. Besides,there are more than 30 articles published in the Journal of Cell, Radiotherapy and Oncology, DNA Repair and the Chinese Journal of Radiation Oncology,and he two successive won the award for "Medical Elite". |
| Selected Publications |
1.Zhao
C, Xiong K, Ji Z, Liu F, Li X P*. The Prognostic Value and Immunological Role
of STEAP1 in Pan-Cancer: A Result of Data-Based Analysis. Oxid Med Cell
Longev. 2022 Mar 11;2022:8297011. 2.Zhao P, Zou J, Zhou F, Zhu Y, Song Q, Yu D, Li X P*. Immune features of COVID-19 convalescent individuals revealed by a single-cell RNA sequencing. Int Immunopharmacol. 2022 Jul;108:108767. doi: 10.1016/j.intimp.2022.108767. Epub 2022 Apr 18. PMID: 35453072; PMCID: PMC9013654. 3.Jiang Y, Li X P*, Yang Y, Luo J, Ren X, Yuan J, Tong Q. LncRNA HOXC-AS1 Sponges miR-99a-3p and Upregulates MMP8, Ultimately Promoting Gastric Cancer. Cancers (Basel). 2022 Jul 20;14(14):3534. doi: 10.3390/cancers14143534. PMID: 35884594; PMCID: PMC9321533. 4.Li X P, Chu Y, Song Q, Hu Q. The Incidence-Based Mortality and Survival Trends in Patients with Gastric Signet Ring Cell Carcinoma. J Oncol. 2022 May 28;2022:3308801. 5.Zhao C, Xiong K, Adam A, Ji Z, Li X P*. Necroptosis Identifies Novel Molecular Phenotypes and Influences Tumor Immune Microenvironment of Lung Adenocarcinoma. Front Immunol. 2022 Jul 14;13:934494. doi: 10.3389/fimmu.2022.934494. PMID: 35911707; PMCID: PMC9331758. 6.Wu L, Liu J, Liang L, Mao M, Li X P*, Li T, Lang J, Wang Q. "Sandwich Therapy"-Immunotherapy Plus Concurrent Chemoradiotherapy for Advanced Esophagogastric Junction Carcinoma: Report of Two Cases and Literature Review. Front Oncol. 2022 May 25;12:794153. 7.Li X P, Chen Q, Ao J, Lin W, Qiu L, Cao R. Synthesis of novel 4,7-disubstituted quinoline derivatives as autophagy inducing agents via targeting stabilization of ATG5. Bioorg Chem. 2022 Jul 3;127:105998. doi: 10.1016/j.bioorg.2022.105998. Epub ahead of print. PMID: 35797861. 8.Li X P, Xiong K, Bi D, Zhao C. A Novel CRISPR/Cas9 Screening Potential Index for Prognostic and Immunological Prediction in Low-Grade Glioma. Front Genet. 2022 Apr 25;13:839884. 9.Zhao C, Xiong K, Zhao F, Adam A, Li X P*. Glycosylation-Related Genes Predict the Prognosis and Immune Fraction of Ovarian Cancer Patients Based on Weighted Gene Coexpression Network Analysis (WGCNA) and Machine Learning. Oxid Med Cell Longev. 2022 Mar 4;2022:3665617. 10.Li N, Xu T, Zhou Z, Li P, Jia G, Li X P*. Immunotherapy Combined With Chemotherapy for Postoperative Recurrent Penile Squamous Cell Carcinoma: A Case Report and Literature Review. Front Oncol. 2022 Mar 23;12:837547. 11.Ren X, Wen W, Fan X, Hou W, Su B, Cai P, Li J, Liu Y, Tang F, Zhang F, Yang Y, He J, Ma W, He J, Wang P, Cao Q, Chen F, Chen Y, Zhong X, Zhang S, Zhu L, Zhu P, Zou B, Zou J, Zuo Z, Bai F, Huang X, Zhou P, Jiang Q, Huang Z, Bei JX, Wei L, Bian XW, Liu X, Cheng T, Li X P*(共同通讯), Zhao P, Wang FS, Wang H, Su B, Zhang Z, Qu K, Wang X, Chen J, Jin R, Zhang Z. COVID-19 immune features revealed by a large-scale single-cell transcriptome atlas. Cell.2021.053(01):1-19. 12.He H, Xu T, Li P, Jia G, Li X P*, Song Q. Anti-PD-1 Immunotherapy Combined With Stereotactic Body Radiation Therapy and GM-CSF as Salvage Therapy in a PD-L1-Positive Patient With Refractory Metastatic Thyroid Hürthle Cell Carcinoma: A Case Report and Literature Review. Front Oncol. 2021 Nov 23;11:782646. 13.Yu D, Hu W, Chen L, Fu Z, Song Q, Li X P*. Effect of radiotherapy interruption due to COVID-19 outbreak - ScienceDirect[J]. Radiotherapy and Oncology, 2021, 155:1-2. 14.Haihua He, Tangpeng Xu, Ping Li, Guohua Jia, Xiangpan Li*, Qibin Song, Anti-PD-1 Immunotherapy Combined With Stereotactic Body Radiation Therapy and GM-CSF as Salvage Therapy in a PD-L1-Positive Patient With Refractory Metastatic Thyroid Hürthle Cell Carcinoma: A Case Report and Literature Review[J]. Frontiers in Oncology, 2021, 23(11):1-6. 15.Ping Li, Lulu Chen, Zheming Liu, Jinghui Pan, Dingyi Zhou, Hui Wang, Hongyun Gong, Zhenmin Fu, Qibin Song, Qian Min, Shasha Ruan, Tangpeng Xu, Fan Cheng*, Xiangpan Li*.Clinical features and short-term outcomes of elderly patients with COVID-19.[J]. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2020, 97 : 245-250. 16.Li, Xiangpan, Zhang, Huibo,Jia, Xuemei,Xu, Liming,Liu, Huali,Chen, Liang,Song, Qibin*,Hui, Zhouguang*.Survival benefit of radiotherapy in metastatic esophageal cancer: a population-based study[J]. Translational Cancer Research, 2019, 8(4) : 1074-1085. 17.Xue, Renyu,Peng, Yihan,Han, Baolin,Li, Xiangpan*,Chen, Yali,Pei, Huadong*. Metastasis suppressor NME1 promotes non-homologous end joining of DNA double-strand breaks.[J]. DNA repair, 2019, 77 : 27-35. 18.Li, Xiangpan, Zhang, Huibo, Wu, Xiaofei*. Long noncoding RNA DLX6-AS1 accelerates the glioma carcinogenesis by competing endogenous sponging miR-197-5p to relieve E2F1[J]. Gene, 2018, 686. 19.Li X P , Wu X . MiR-21-5p promotes the progression of non-small-cell lung cancer by regulating the expression of SMAD7[J]. Oncotargets & Therapy, 2018, Volume 11:8445-8454. 20.李祥攀,张惠博,俞建雄，俞建雄,宋启斌,肖建平..放射治疗对转移性鼻咽癌生存的影响——基于SEER数据库的回顾性研究[J].中华放射肿瘤学杂志, 2019, 28(1):5-12. |
武汉大学人民医院
湖北省人民医院